Resources
30 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 4/20/2022 (updated 3/27/2024)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 6/8/2023 (updated 3/27/2024)
There are multiple systems that can help individuals to address substance use disorder (SUD). A new report from the Addiction and Public Policy Initiative of the O’Neill Institute for National and Global Health Law at Georgetown Law Center discusses how these multiple systems are often disjointed which creates barriers for those needing to access services for SUD.
Posted 2/14/2023 (updated 3/27/2024)
This systematic review of peer-reviewed literature that held controlled trails which examined a pharmacological treatment for amphetamine/methamphetamine dependence or use disorder. The article found that most studies were underpowered and had low completion rates, with others showing that no pharmacotherapy produced results for the treatment of amphetamine/methamphetamine dependence.
Posted 6/22/2023 (updated 3/28/2024)
The Practical Guide for Implementing a Trauma-Informed Approach was developed by SAMHSA. The guide focuses on tools and strategies for implementing a Trauma-Informed Approach across ten domains.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 11/21/2019 (updated 3/28/2024)
This report is designed to help drug court practitioners understand medication assisted treatment (MAT) for opioid addiction and to provide strategies for incorporating MAT into their practice.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.